The sale is part of Novo Nordisk’s proposed acquisition of Catalent, a contract development and manufacturing organization based in Somerset, N.J. The three facilities are in Italy, Belgium and Bloomington, Ind., and employ more than 3,000 people, according to a Feb. 5 news release.
The facilities are equipped for sterile filling, and Novo Nordisk said the fill-finish sites will focus on increasing supply of its diabetes and obesity treatments starting in 2026.
